Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.45 |
| ▸ | F7 | P08709 | 1/20 | 0.44 |
| ▸ | F3 | P13726 | 1/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30189253 | 1.00 | KDM4E (0.47) | KDM4EHSD17B10HPGDALDH1A1LMNA | |
| SCHEMBL30147627 | 0.82 | ALOX15 (0.46) | KDM4EALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL831147 | 0.79 | KDM4E (0.54) | KDM4EHSD17B10HPGDALDH1A1LMNA | |
| SCHEMBL30104780 | 0.79 | KDM4E (0.54) | KDM4EHSD17B10HPGDALDH1A1LMNA | |
| SCHEMBL30189257 | 0.79 | KDM4E (0.56) | KDM4EHSD17B10HPGDALDH1A1LMNA | |
| SCHEMBL29301419 | 0.79 | KDM4E (0.56) | KDM4EHSD17B10HPGDALDH1A1LMNA | |
| SCHEMBL1100416 | 0.77 | CHRM1 (0.43) | KDM4EHSD17B10APEX1PIN1SMN1; SMN2 | |
| SCHEMBL14972759 | 0.76 | HSD17B10 (0.41) | KDM4EHSD17B10HPGDALDH1A1LMNA | |
| SCHEMBL25219154 | 0.76 | PIN1 (0.56) | KDM4EHSD17B10HPGDALDH1A1LMNA | |
| SCHEMBL2105708 | 0.76 | SMAD3 (0.49) | KDM4EHSD17B10HPGDALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| CN-117396485-A | PARP7 inhibitors | 轩竹生物科技股份有限公司 | 2024-01-12 | — | — | CN | disclosed |
| EP-4149945-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2023-03-22 | — | — | EP | disclosed |
| WO-2022247839-A1 | PARP7 INHIBITOR | 山东轩竹医药科技有限公司 | 2022-12-01 | — | — | WO | disclosed |
| WO-2021229302-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-11-18 | — | — | WO | disclosed |
| CN-101247808-B | N- (arylalkyl) -1H-pyrrolopyridine-2-carboxamide derivatives and their preparation | SANOFI AVENTIS | 2014-08-27 | — | — | CN | disclosed |
| US-8716272-B2 | N-(amino-heteroaryI)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy | SANOFI (FR) | 2014-05-06 | — | — | US | disclosed |
| US-8716273-B2 | N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy | SANOFI (FR) | 2014-05-06 | — | — | US | disclosed |
| EP-2125811-B1 | N-(AMINO-HETEROARYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDES DERIVATIVES, PREPARATION THEREOF AND THEIR USE IN THERAPY | SANOFI SA (FR) | 2013-05-29 | — | — | EP | disclosed |
| US-20100041634-A1 | N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy | SANOFI-AVENTIS (FR) | 2010-02-18 | — | — | US | disclosed |
| EP-1912644-B1 | N-(ARYLALKYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF | SANOFI AVENTIS (FR) | 2009-12-16 | — | — | EP | disclosed |
| CN-101379041-A | Tricyclic N-heteroaryl-amide derivatives containing benzimidazole structural units, their preparation and their therapeutic use | SANOFI AVENTIS (FR) | 2009-03-04 | — | — | CN | disclosed |
| US-20090042873-A1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2009-02-12 | — | — | US | disclosed |
| EP-1987010-A1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | Sanofi-Aventis (FR) | 2008-11-05 | — | — | EP | disclosed |
| CN-101247808-A | N- (arylalkyl) -1H-pyrrolopyridine-2-carboxamide derivatives, their preparation and their therapeutic use | SANOFI AVENTIS (FR) | 2008-08-20 | — | — | CN | disclosed |
| US-20080125459-A1 | N-(ARYLALKYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-05-29 | — | — | US | disclosed |
| EP-1912644-A2 | N-(ARYLALKYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF | Sanofi-Aventis (FR) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007088277-A1 | TRICYCLIC Ν-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007010138-A2 | N(ARYLALKYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125459-A1 | N-(ARYLALKYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | CYP3A5, ZYX, ZDHHC2 | KDM4E 1484/4885HSD17B10 2829/4885HPGD 1088/4885 |
| US-20090042873-A1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | CYP3A5, CYP2C8, PAICS | KDM4E 1797/4885HSD17B10 1941/4885HPGD 2336/4885 |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | SLC10A1, NR1H4, SLC10A2 | KDM4E 1496/4885HSD17B10 237/4885HPGD 808/4885 |
| US-20100041634-A1 | N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy | ZYX, NQO2, PYCR1 | KDM4E 804/4885HSD17B10 3313/4885HPGD 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.